Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 safety and tolerability study of IC51 Japanese encephalitis vaccine versus placebo
2005-000100-14Phase 3Completed
- Sponsor
- Intercell AG
- Start
- Jan 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Intercell AG. Primary endpoint: Rate of serious adverse events and medically attended adverse events. Started Jan 2005; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2005-000100-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000100-14.